miRNA-22 as a Candidate Diagnostic Biomarker for Coronary Slow Flow
Table 1
General clinical data.
Characteristic
Control group (n = 42)
Coronary slow flow group (n = 44)
value
Male (n, %)
30 (71.43)
32 (72.73)
0.8948
Age (years)
54.19 ± 6.213
56.48 ± 9.891
0.2052
BMI (kg/m2)
25.38 ± 2.083
25.57 ± 3.022
0.7400
Systolic pressure (mmHg)
125.9 ± 10.22
122.5 ± 7.981
0.0840
Diastolic blood pressure (mmHg)
73.93 ± 6.968
75.52 ± 7.013
0.2935
Heart rate (bpm)
72.40 ± 6.409
73.00 ± 7.314
0.6897
Fasting blood glucose (mmol/L)
5.363 ± 0.7273
5.641 ± 1.089
0.1691
Triglyceride (mmol/L)
1.522 ± 0.4450
1.626 ± 0.4848
0.3004
Total cholesterol (mmol/L)
4.620 ± 1.121
4.710 ± 1.252
0.7262
High-density lipoprotein (mmol/L)
1.177 ± 0.2796
1.156 ± 0.2024
0.6898
Low-density lipoprotein (mmol/L)
2.789 ± 0.5427
2.538 ± 0.6474
0.0559
Smoker (n, %)
6 (14.29)
8 (18.18)
0.6295
Alcohol consumption (n, %)
8 (19.05)
12 (27.27)
0.3727
Hypertension (n, %)
7 (16.67)
9 (20.45)
0.6564
Diabetes (n, %)
5 (11.9)
6 (13.64)
0.8128
Hyperlipidemia (n, %)
22 (52.38)
26 (59.09)
0.5367
Calcium antagonist (n, %)
5 (11.9)
7 (15.91)
0.5973
ARB/ACEI (n, %)
28 (66.67)
31 (70.45)
0.7092
β-blocker (n, %)
29 (69.05)
29 (65.91)
0.7596
Nitrate ester (n, %)
7 (16.67)
9 (20.45)
0.6564
Statins (n, %)
39 (92.86)
42 (95.45)
0.6119
Antiplatelet drug (n, %)
42 (100.0)
44 (100.0)
ND
miRNA-22
0.97 ± 0.06
3.28 ± 0.29
<0.001
BMI, body mass index; ARB/ACEI, angiotensin receptor blocker/angiotensin-converting enzyme inhibitor (continuous variables with normal distribution were expressed as mean ± SD).
